These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26831328)

  • 41. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
    Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
    PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
    Belley A; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of long-acting antibiotics in the clinical practice: a narrative review.
    Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
    Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.
    Schulz LT; Dworkin E; Dela-Pena J; Rose WE
    Pharmacotherapy; 2018 Jan; 38(1):152-159. PubMed ID: 29121395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study.
    Anastasio PJ; Wolthoff P; Galli A; Fan W
    Infect Dis Ther; 2017 Mar; 6(1):115-128. PubMed ID: 28078655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oritavancin for skin infections.
    Anderson DL
    Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
    Ambrose PG; Drusano GL; Craig WA
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S220-8. PubMed ID: 22431852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel pharmaceutical molecules against emerging resistant gram-positive cocci.
    Manfredi R; Sabbatani S
    Braz J Infect Dis; 2010; 14(1):96-108. PubMed ID: 20428664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of oritavancin for the treatment of acute bacterial skin and skin structure infections.
    García Robles AA; López Briz E; Fraga Fuentes MD; Asensi Diez R; Sierra Sánchez JF
    Farm Hosp; 2018 Mar; 42(2):73-81. PubMed ID: 29501059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF; Seguin DL; Belley A; Moeck G
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
    Van Bambeke F
    Ann Med; 2014 Nov; 46(7):512-29. PubMed ID: 25058176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Use of Oritavancin for the Treatment of Osteomyelitis.
    Scoble PJ; Reilly J; Tillotson GS
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):46-54. PubMed ID: 32588387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
    Karlowsky JA; Walkty AJ; Baxter MR; Arhin FF; Moeck G; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2017 Apr; 87(4):349-356. PubMed ID: 28159446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
    Pfaller MA; Sader HS; Flamm RK; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):199-204. PubMed ID: 29567128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience.
    Brownell LE; Adamsick ML; McCreary EK; Vanderloo JP; Ernst EJ; Jackson ER; Schulz LT
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):13-19. PubMed ID: 32592120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.